The objective of this application is to conduct a clinical trial of APT-3 combined with targeted neuromodulation to treat cognitive control deficits in complex mTBI. Veterans and Servicemembers with mTBI and cognitive symptoms will be recruited from the New Mexico and Minneapolis VA Polytrauma clinics. Participants will undergo baseline demographic, neuropsychological, and quality of life testing, as well as resting/task-related fMRI. They will be randomized to 4 weeks of computer-based APT with concurrent rTMS, HD-tDCS, or sham stimulation delivered to the dorsolateral prefrontal cortex (DLPFC). Lastly, they will repeat all baseline tests, and report on 3- and 6-monthrecovery levels. Our central hypotheses are: (Aim 1) targeted neuromodulation applied to the DLPFC, when paired with APT-3, will facilitate the greatest improvement in cognitive control for the rTMS group (rTMS>HD-tDCS>sham); (Aim 2) these interventions will result in improvements in functional measures and quality of life; (Aim 3) fMRI will identify changes in CCN activation associated with cognitive control deficits and recovery.